{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:25:10Z","timestamp":1792855510402,"version":"4.5.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Psoriasis is a chronic inflammatory skin disorder with systemic implications, including an elevated risk of cardiovascular disease (CVD). The interaction between psoriasis severity, metabolic abnormalities, and systemic inflammation may contribute to cardiovascular comorbidities. However, the clinical characteristics and predictors of CVD in psoriasis patients remain incompletely understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective cohort study of 320 adult patients with psoriasis. Participants were categorized into two groups according to cardiovascular status (psoriasis with CVD vs. psoriasis without CVD). Demographic, clinical, metabolic, and inflammatory parameters were compared. Variable selection was performed using LASSO regression, followed by multivariable logistic regression to identify independent predictors of CVD. Kaplan\u2013Meier curves and Cox proportional hazards models were applied to evaluate survival outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 320 psoriasis patients, 88 (27.5%) had cardiovascular comorbidities. Compared with controls, patients with CVD were significantly older, had longer psoriasis duration, higher body mass index, and more severe disease (mean PASI 12.8 vs. 9.7, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). They also exhibited higher prevalence of hypertension (68.2% vs. 20.7%), diabetes (25.0% vs. 10.3%), and dyslipidemia (50.0% vs. 22.4%), as well as elevated C\u2013reactive protein levels. Multivariable regression identified older age, longer disease duration, higher PASI scores, hypertension, diabetes, and CRP as independent predictors of CVD. Kaplan\u2013Meier analysis showed that severe psoriasis combined with hypertension conferred the greatest risk, with a significantly lower CVD\u2013free survival probability (adjusted HR: 3.56, 95% CI: 2.01\u20136.31).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Psoriasis patients with cardiovascular comorbidities demonstrate a distinct clinical and inflammatory profile. Our findings underscore the importance of integrated management, with aggressive control of both psoriasis severity and traditional risk factors to mitigate cardiovascular burden. Future prospective studies should evaluate whether targeted anti\u2013inflammatory therapies can reduce cardiovascular outcomes in psoriasis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1586731","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T14:55:26Z","timestamp":1759503326000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical characteristics and influencing factors of cardiovascular comorbidities in psoriasis"],"prefix":"10.3389","volume":"12","author":[{"given":"Xinrui","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15707","DOI":"10.3390\/ijms242115707","article-title":"From the skin to distant sites: t cells in psoriatic disease","volume":"24","author":"Reali","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/adt.2023.014","article-title":"Psoriasis: striving for potential biomarkers","volume":"21","author":"Dan","year":"2023","journal-title":"Assay Drug Dev Technol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s13671-011-0005-3","article-title":"A review of the epidemiology of cardiovascular comorbidities in psoriasis","volume":"1","author":"Lee","year":"2012","journal-title":"Curr Dermatol Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1055\/s-0040-1705661","article-title":"Determinants of cardiovascular disease among urban women with psoriasis: a case\u2013control study","volume":"5","author":"Bala","year":"2020","journal-title":"Indian J Cardiovasc Dis Women WINCARS"},{"key":"B5","first-page":"13","article-title":"Considerations for cardiovascular risk in patients with psoriasis","volume":"45","author":"Andrus","year":"2024","journal-title":"Dermatol Times"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3390\/jcm12031162","article-title":"Biologics for reducing cardiovascular risk in psoriasis patients","volume":"12","author":"Terui","year":"2023","journal-title":"J Clin Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"ehz745.0843","DOI":"10.1093\/eurheartj\/ehz745.0843","article-title":"P4442miR-200c is up-regulated in lesional skin and plasma of patients affected by psoriasis and correlates with disease severity and cardiovascular risk","volume":"40","author":"Magenta","year":"2019","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"adv00020","DOI":"10.2340\/00015555-3375","article-title":"Psoriasis and mental health workshop report: exploring the links between psychosocial factors, psoriasis, neuroinflammation and cardiovascular disease risk","volume":"100","author":"Kleyn","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1238647","DOI":"10.3389\/fimmu.2023.1238647","article-title":"Platelet activation: a promoter for psoriasis and its comorbidity, cardiovascular disease","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/1756-185X.13421","article-title":"Polyarticular evolution and late-onset psoriasis may be associated with cardiovascular disease in psoriatic arthritis","volume":"22","author":"Queiro","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000491819","article-title":"Decreased systemic levels of endocan-1 and CXCL16 in psoriasis are restored following narrowband UVB treatment","volume":"234","author":"Sigurdardottir","year":"2018","journal-title":"Dermatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4274\/turkderm.01709","article-title":"Evaluation of serum asymmetric dimethylarginine levels in patients with psoriasis vulgaris","volume":"49","author":"Bilgi\u00e7","year":"2015","journal-title":"Turkderm"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1038\/jid.2009.112","article-title":"The risk of stroke in patients with psoriasis","volume":"129","author":"Gelfand","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.jaad.2022.08.027","article-title":"Association of the triglyceride-glucose index with insulin resistance and subclinical atherosclerosis in psoriasis: an observational cohort study","volume":"88","author":"O\u2019hagan","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.jid.2024.02.015","article-title":"Monocyte-to-high-density lipoprotein ratio is associated with systemic inflammation, insulin resistance and coronary subclinical atherosclerosis in psoriasis: results from two observational cohorts","volume":"144","author":"Berna-Rico","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1590\/abd1806-4841.20165080","article-title":"Psoriasis comorbidities: complications and benefits of immunobiological treatment","volume":"91","author":"de Carvalho","year":"2016","journal-title":"An Bras Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"510","DOI":"10.4103\/0378-6323.183638","article-title":"Prevalence of metabolic syndrome and cardiovascular changes in patients with chronic plaque psoriasis and their correlation with disease severity: a hospital-based cross-sectional study","volume":"82","author":"Kothiwala","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5152\/eurjrheum.2019.19029","article-title":"Are there any differences among psoriasis, psoriatic arthritis and rheumatoid arthritis in terms of metabolic syndrome and cardiovascular risk factors?","volume":"6","author":"\u00d6zkul","year":"2019","journal-title":"Eur J Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1111\/ajd.12577","article-title":"Factors influencing cardiometabolic risk profile in patients with psoriasis","volume":"59","author":"Curc\u00f3","year":"2018","journal-title":"Australas J Dermatol"},{"key":"B21","first-page":"18","article-title":"Psoriatic march: a view from pathophysiology to cardiovascular risk","volume":"31","author":"Soto","year":"2024","journal-title":"Rev Colomb Reumatol (English Edition)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jid.2020.07.012","article-title":"Enhanced inflammasome activity in patients with psoriasis promotes systemic inflammation","volume":"141","author":"Verma","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12916-022-02617-5","article-title":"Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"105485","DOI":"10.1016\/j.ebiom.2024.105485","article-title":"Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasis","volume":"111","author":"Kridin","year":"2024","journal-title":"EBioMedicine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1001\/jamadermatol.2022.3862","article-title":"Association of apremilast with vascular inflammation and cardiometabolic function in patients with psoriasis: the VIP-A phase 4, open-label, nonrandomized clinical trial","volume":"158","author":"Gelfand","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","article-title":"A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","article-title":"A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e007394","DOI":"10.1161\/CIRCIMAGING.117.007394","article-title":"Effect of two psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial","volume":"11","author":"Mehta","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S0022-202X(25)00377-X","DOI":"10.1016\/j.jid.2025.03.014","article-title":"Residual inflammation in patients with psoriasis treated with biologic therapy: findings from three prospective observational cohorts","author":"Lecumberri","year":"2025","journal-title":"J Invest Dermatol"},{"key":"B30","first-page":"113","article-title":"The impact of shared assistance between dermatology and internal medicine on patients with psoriasis","volume":"1","author":"Malinis","year":"2024","journal-title":"J Clin"},{"key":"B31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jamadermatol.2021.4467","article-title":"Analysis of specialist and patient perspectives on strategies to improve cardiovascular disease prevention among persons with psoriatic disease","volume":"158","author":"Barbieri","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"adv5087","DOI":"10.2340\/actadv.v103.5087","article-title":"Cardiovascular screening practices and statin prescription habits in patients with psoriasis among dermatologists, rheumatologists and primary care physicians","volume":"103","author":"Berna-Rico","year":"2023","journal-title":"Acta Derm Venereol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1586731\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T14:55:27Z","timestamp":1759503327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1586731\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":32,"alternative-id":["10.3389\/fcvm.2025.1586731"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1586731","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"article-number":"1586731"}}